Monitor finalization of the DOJ settlement documentation and any further developments in other Respironics-related proceedings. The reiterated guidance and strong order intake suggest stable near-term performance, but the macro environment and tariff uncertainties remain key watchpoints.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $28.46entry
- T+1 · 13d ago +9.14%α +7.48% · $31.06
- T+5 · 7d ago +6.85%α +7.44% · $30.41
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Philips reported Q3 2026 comparable sales growth of 3% and adjusted EBITA margin expansion of 70 bps to 13.0%, while reiterating full-year 2026 guidance. The company also recorded a EUR 288 million provision for a Respironics DOJ settlement agreement in principle, which is expected to be paid in Q1 2027.
Key Financial Metrics
Key Facts
- Comparable order intake grew 8% in Q3 2026, driven by Diagnosis & Treatment.
- Comparable sales increased 3% to EUR 4.4 billion.
- Adjusted EBITA margin improved 70 bps to 13.0%.
- Operating cash flow was EUR 544 million; free cash flow was EUR 384 million.
- Philips reiterated full-year 2026 outlook: comparable sales growth 3%-4.5%, adjusted EBITA margin 13.5%-14.0%, free cash flow EUR 1.5-1.7 billion.
- Recorded a EUR 288 million provision for Respironics DOJ settlement in principle; payment expected Q1 2027.
- Issued EUR 650 million green bonds under the EU Green Bond Standard.
- Productivity program delivered EUR 170 million net savings in Q3, EUR 427 million year-to-date.
Financial Impact
EUR 288 million provision for DOJ settlement; EUR 650 million green bond issuance; EUR 384 million free cash flow in Q3.
Segment Breakdown
| Segment | Growth |
|---|---|
| Diagnosis & Treatment | 0.0% |
| Connected Care | +5.0% |
| Personal Health | +8.0% |
Risk Factors
- DOJ settlement finalization and payment in Q1 2027 could impact cash flow.
- Ongoing Respironics-related investigations by US State Attorneys General remain unresolved.
- Macroeconomic and tariff uncertainties may affect full-year outlook achievement.
- China sales decline in Precision Diagnosis segment may persist.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393896 |
Track record
12 reports on PHG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Viewing Entry $28.46 Now $30.14 +5.90% settles Feb 1
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $27.12 Now $30.14 +11.14% settles Jan 27
- Aug 27, 202611w ago Press Release Neutral 3/10 Entry $26.92 Now $30.14 +11.96% settles Nov 20
- Aug 24, 202612w ago Press Release Neutral 3/10 Entry $27.43 Now $30.14 +9.88% settles Nov 18
- Jul 27, 202616w ago Press Release Mixed 6/10 Entry $25.02 to $26.00 Now $30.14 +20.46% ▲ +3.92% −0.14% vs SPY
- Jun 2, 202623w ago Press Release Neutral 2/10 Entry $25.43 to $26.99 Now $30.14 +18.52% ▲ +6.13% +5.02% vs SPY
- May 15, 202626w ago Court Ruling Bullish 4/10 Entry $26.05 to $27.38 Now $30.14 +15.70% ▲ +5.11% −0.48% vs SPY
- May 6, 202627w ago Press Release Neutral 4/10 Entry $27.23 to $26.23 Now $30.14 +10.69% ▼ −3.67% −7.19% vs SPY
- Mar 23, 202634w ago Press Release Neutral 3/10 Entry $26.81 to $26.24 Now $30.14 +12.42% ▼ −2.13% −15.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers